HanchorBio to Present FBDB™ Platform Strategy and Clinical Pipeline Progress at BIO Asia–Taiwan 2026
[Taipei, Shanghai, San Francisco | July 13, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will participate in BIO Asia–Taiwan 2026, taking place from July 16 to 19, 2026, in Taipei, Taiwan. During the conference, the Company will highlight its proprietary FBDB™ multi-functional fusion protein technology platform, its oncology development strategy centered on HCB101, and the clinical progress of its key pipeline assets.
At this year’s conference, HanchorBio will present its development strategy under the theme of “clinical anchoring and platform expansion.” The Company will share updates on HCB101, its engineered SIRPα-Fc fusion protein, including early clinical progress in second-line gastric/gastroesophageal junction cancer and head and neck cancer. HanchorBio will also discuss the differentiated design of HCB101, including its tumor-binding profile and reduced risk of red blood cell binding, which supports its continued development as a potential backbone therapy for combination treatment strategies.
In addition, HanchorBio will showcase how clinical learnings from HCB101 are being applied to the broader expansion of its FBDB™ platform, including the development of HCB301, HCB303, and additional combination approaches. This reflects the Company’s long-term strategy to leverage a platform-driven model to generate differentiated biologic drug candidates and support global partnering opportunities.
HanchorBio’s proprietary FBDB™ platform is designed to create multi-functional fusion proteins that may help address limitations of current cancer therapies. Through its dual immune-modulating mechanism, the platform is intended to engage both innate and adaptive immunity, supporting immune responses involved in tumor clearance. To date, the platform has generated more than eight biologic drug candidates across solid tumors, hematologic malignancies, and autoimmune diseases, demonstrating its potential flexibility across multiple therapeutic areas.
The Company has continued to advance both clinical development and business development activities. Its two core clinical-stage assets, HCB101 and HCB301, are currently being evaluated in clinical studies across the United States, China, and Taiwan, with HCB101 in Phase 1b/2a development and HCB301 in Phase 1 development. In June 2025, HCB101 achieved a key business milestone through a licensing agreement with Henlius, with a total potential deal value of up to US$202 million. This transaction further supported the commercial potential of the FBDB™ platform and established an important foundation for HanchorBio’s future global licensing and collaboration strategy.
Following its registration on Taiwan’s Emerging Stock Market in 2025, HanchorBio successfully listed on the Taiwan Stock Exchange’s Taiwan Innovation Board in 2026. The Company also introduced OrbiMed, a leading global healthcare investment firm, as a strategic investor, further strengthening its capital base and supporting the continued advancement of its clinical programs and global business development initiatives.
“BIO Asia–Taiwan is an important platform for HanchorBio to engage with the global biotechnology community,” said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. “Through this conference, we look forward to deepening discussions with potential licensing partners, multinational pharmaceutical companies, and institutional investors as we continue to advance our differentiated pipeline and explore new opportunities for product licensing and co-development.”
Looking ahead, HanchorBio will continue to integrate its proprietary platform technology, clinical development capabilities, AI-enabled research, and global capital market connections to accelerate the development of differentiated biologic therapies. With a continued focus on oncology and autoimmune diseases, the Company remains committed to addressing significant unmet medical needs and bringing innovative treatment options to patients worldwide.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康-KY亮相2026亞洲生技大會！展現FBDB™獨家平台拓展策略
亞太區年度生技盛事「2026亞洲生技大會（BIO Asia–Taiwan 2026）」隆重登場，專注創新藥物開發的漢康-KY（股票代碼：7827）今（13）日表示，將於大會期間全面展示自主研發的FBDB™多功能融合蛋白技術平台、以 HCB101 為核心延伸出的腫瘤免疫研發策略，以及核心資產的臨床進展。此舉彰顯漢康-KY在創新生物藥開發、臨床推進與國際合作布局上的持續進展，並有望吸引全球資本與跨國藥廠的關注。
此次展期，漢康-KY將以「臨床定錨、平台拓展」為主軸，全面展示 HCB101 於二線胃癌／胃食道交界癌及頭頸癌的早期臨床進展，並說明其工程化 SIRPα 融合蛋白在腫瘤結合與紅血球低結合風險上的差異化設計，支持後續聯合療法的開發。同時，公司也將呈現平台拓展策略，從 HCB101 的臨床驗證延伸至 HCB301、HCB303 及更多聯合療法布局，展現漢康以平台驅動創新藥物開發與國際合作的長期價值。
亞洲生技大展 BioAsia 大會資訊
時間｜7/16（四）-19（日）10:00–18:00 (最後一日至17:00)
地點｜台北南港展覽館一館 4F
漢康生技攤位號｜L221展位
公司展望說明會
時間｜7/17（五）15:45–16:00
地點｜台北南港展覽館一館 4F，N913 展位
主講人｜漢康生技 研發長 翟文武博士
漢康-KY深耕腫瘤免疫與自體免疫疾病領域，自主建立的FBDB™技術平台，期透過創新的融合蛋白設計突破現行癌症治療療效限制的瓶頸。該平台具有「同時啟動先天性與適應性免疫系統」獨特的雙重免疫機制，有助於提升腫瘤清除相關免疫反應。
透過高效的平台化設計，漢康-KY已成功衍生超過8項候選藥物，應用範圍橫跨實體腫瘤、血液腫瘤及自體免疫疾病，展現「一平台、多應用」的開發彈性。
在產品轉化效率方面，漢康-KY展現出高度的國際執行力，臨床進度與商務拓展雙軌並進。旗下兩大核心資產HCB101與HCB301已分別推進至臨床1b/2a期及1期階段，並於美國、中國大陸及台灣同步展開收案。其中，HCB101於去年6月成功以總授權金額高達2.02億美元的指標性規模，授權給港股上市生物藥企復宏漢霖。此重大里程碑進一步驗證FBDB™平台的商業變現潛力，也為漢康-KY後續推進國際授權與合作奠定重要基礎。
漢康-KY於2025年登錄興櫃後，隨即於2026年順利掛牌創新板上市，在資本市場的表現亦備受矚目。上市前的詢價圈購階段即引發國內外機構投資人高度搶購，更成功引進全球頂尖醫療健康投資機構—奧博資本（OrbiMed）作為策略投資人。國際專業醫療投資機構的參與，充分顯現資本市場對漢康-KY技術平台與臨床開發潛力的認可，亦為公司後續的臨床推進與全球商務拓展提供資金與資源後盾。
董事長劉世高表示，參與2026亞洲生技大會是公司邁向全球市場的重要戰略之一。期望藉由亞太區內最具影響力的生技交流盛會，與全球潛在授權夥伴、跨國藥廠及頂尖機構投資人展開深度對話，全力推動新一輪的產品授權與共同開發合作。
展望未來，漢康-KY將持續融合獨家平台技術、臨床開發、AI研發賦能以及國際資本市場的鏈結力，加速將具差異化潛力的創新生物藥推向全球。公司將以腫瘤免疫與自體免疫疾病為核心方向，致力於為未被滿足的醫療需求提供創新治療選擇。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。
聲明：
本新聞稿及同時發佈之相關資訊內含有預測性敘述；其內容乃根據既有之風險及可能的不確定性進行判斷及預測，包括：市場因素與其他非漢康-KY（以下簡稱本公司）所能掌控之原因。這些預測性敘述是基於現況的預測和評估，除非基於法律的要求，本公司不負日後更新之責。